zollinger-ellison%20syndrome
ZOLLINGER-ELLISON SYNDROME
Zollinger-Ellison syndrome (ZES) is a disease entity which refers to the triad of severe peptic ulcer disease (PUD), gastric acid hypersecretion and non-beta cell gastrin-secreting tumor primarily of the pancreas and duodenum (gastrinoma).
Approximately two-thirds of patients have sporadic ZES while the rest is part of multiple endocrine neoplasia type 1.
ZES should be considered in the differential diagnoses of patients who present with abdominal pain, malabsorption and chronic watery diarrhea.
A high index of clinical awareness is necessary to correctly diagnose ZES.
Drug Information

Indication: Peptic ulcer disease associated w/ H pylori.

Indication: Healing & maintenance of erosive or ulcerative GERD. Healing of duodenal ulcers. Pathological hypersecreto...

Indication: Active duodenal, benign gastric, stomal & recurrent ulceration, persistent dyspeptic symptoms w/ or w/o ul...

Indication: Duodenal & gastric ulcer, reflux esophagitis, Zollinger-Ellison syndrome.

Indication: Duodenal & gastric ulcer, Zollinger-Ellison syndrome & other conditions associated w/ gastric hyperaci...

Indication: Peptic ulcer associated w/ H pylori.

Indication: Reflux disease & associated symptoms. Prevention of gastroduodenal ulcers induced by NSAIDs in patients at...

Indication: 20 mg Mild GERD & associated symptoms (eg, heartburn, acid regurgitation, pain on swallowing). Long-term m...

Indication: Duodenal & gastric ulcer, reflux oesophagitis, symptomatic GERD, Zollinger-Ellison syndrome. Prophylaxis &...

Indication: Duodenal & gastric ulcer. NSAID-associated gastric & duodenal ulcers or erosions. H pylori eradication...

1  /  7
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.